Terms: = Prostate cancer AND MPL, TPOR, P40238, 4352, ENSG00000117400, CD110, MPLV, C-MPL, RP1-92O14_1
64287 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract] [Full Text] [Related]
3. prostate intra-fraction motion recorded by transperineal ultrasound.
Ballhausen H; Belka C; Li M
Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
[TBL] [Abstract] [Full Text] [Related]
4. When to reinvite initially ineligible populations for targeted lung cancer screening?
Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
[TBL] [Abstract] [Full Text] [Related]
5. Determinants and Factors of Physical Activity After Oncology Treatments (DEFACTO) in Metropolitan France: Protocol of a Mixed Methods Study and Intervention.
Aumaitre A; Gagnayre R; Foucaut AM
JMIR Res Protoc; 2024 May; 13():e52274. PubMed ID: 38753415
[TBL] [Abstract] [Full Text] [Related]
6. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
[TBL] [Abstract] [Full Text] [Related]
7. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
8. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
[TBL] [Abstract] [Full Text] [Related]
9. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
Ullah A; Jiao W; Shen B
Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
[TBL] [Abstract] [Full Text] [Related]
10. WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.
Cheng J; Huo D; Zhang Z; Zhang J; Dong B; Liu Z; Zhou Z; Lu Y
Med Oncol; 2024 May; 41(6):151. PubMed ID: 38743149
[TBL] [Abstract] [Full Text] [Related]
11. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer.
Laurberg T; Witte DR; Gudbjörnsdottir S; Eliasson B; Bjerg L
Sci Rep; 2024 May; 14(1):10956. PubMed ID: 38740921
[TBL] [Abstract] [Full Text] [Related]
12. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
[TBL] [Abstract] [Full Text] [Related]
13. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract] [Full Text] [Related]
14. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
Scilipoti P; Liedberg F; Garmo H; Wilberg Orrason A; Stattin P; Westerberg M
Scand J Urol; 2024 May; 59():98-103. PubMed ID: 38738332
[TBL] [Abstract] [Full Text] [Related]
15. Hematological and renal toxicity in mice after three cycles of high activity [
Kristiansson A; Vilhelmsson Timmermand O; Altai M; Strand SE; Åkerström B; Örbom A
Sci Rep; 2024 May; 14(1):10787. PubMed ID: 38734765
[TBL] [Abstract] [Full Text] [Related]
16. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
[TBL] [Abstract] [Full Text] [Related]
17. Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on cancer Cell Lines.
Albani M; Fassi EMA; Moretti RM; Garofalo M; Montagnani Marelli M; Roda G; Sgrignani J; Cavalli A; Grazioso G
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731842
[TBL] [Abstract] [Full Text] [Related]
18. CD8
Iyer RF; Verweij MC; Nair SS; Morrow D; Mansouri M; Chakravarty D; Beechwood T; Meyer C; Uebelhoer L; Lauron EJ; Selseth A; John N; Thin TH; Dzedzik S; Havenar-Daughton C; Axthelm MK; Douglas J; Korman A; Bhardwaj N; Tewari AK; Hansen S; Malouli D; Picker LJ; Früh K
Sci Adv; 2024 May; 10(19):eadm7515. PubMed ID: 38728394
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from prostate cancer Patients.
Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
Cells; 2024 May; 13(9):. PubMed ID: 38727318
[TBL] [Abstract] [Full Text] [Related]
20. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
[Next]
